A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

Official title

A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants With Advanced Solid Tumors

Overview

This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.

Interventions

• Drug OBI-902
  OBI-902 is an antibody-drug conjugate study drug

Primary outcome measures

• Safety and tolerability of OBI-902: incidence of adverse events (AEs) and serious adverse events (SAEs), changes in selected clinical laboratory parameters, cardiac parameters, and vital signs. [Time frame: Duration of study, up to 54 weeks]
• Maximum tolerated dose (MTD) of OBI-902 [Time frame: Duration of study, up to 54 weeks]
• Preliminary antitumor activity of OBI-902 in selected tumor types - Objective Response Rate (ORR) [Time frame: Duration of study, up to 54 weeks]
• Preliminary antitumor activity of OBI-902 in selected tumor types - Duration of Response (DoR) [Time frame: Duration of study, up to 54 weeks]
• Preliminary antitumor activity of OBI-902 in selected tumor types - Clinical Benefit Rate (CBR) [Time frame: Duration of study, up to 54 weeks]
• Preliminary antitumor activity of OBI-902 in selected tumor types - Disease Control Rate (DCR) [Time frame: Duration of study, up to 54 weeks]
• Safety and tolerability of OBI-902 in Phase 1b/Phase 2: incidence of AEs, SAEs, and laboratory abnormalities. [Time frame: Duration of study, up to 54 weeks]
• Optimal recommended phase 2 dose (RP2D) of OBI-902 [Time frame: Duration of study, up to 54 weeks]

Secondary outcome measures (7)

• Preliminary long-term efficacy of OBI-902 in selected tumor types [Time frame: Duration of study, up to 54 weeks]
• Pharmacokinetics (PK) of OBI-902 and exatecan: Peak Plasma Concentration (Cmax) [Time frame: Duration of study, up to 54 weeks]
• Pharmacokinetics (PK) of OBI-902 and exatecan: area under the concentration-time curve (AUC) [Time frame: Duration of study, up to 54 weeks]
• Pharmacokinetics (PK) of OBI-902 and exatecan: half-life (T1/2) [Time frame: Duration of study, up to 54 weeks]
• Pharmacokinetics (PK) of OBI-902 and exatecan: clearance (CL) [Time frame: Duration of study, up to 54 weeks]
• Pharmacokinetics (PK) of OBI-902 and exatecan: volume distribution at steady state (Vdss) [Time frame: Duration of study, up to 54 weeks]
• Immunogenicity of OBI-902 [Time frame: Duration of study, up to 54 weeks]

Eligibility criteria

Inclusion criteria

• Male or female participants, 18 years of age or older at the time of consent
• Provide written informed consent prior to performing any study-related procedure
• Histologically or cytologically confirmed participants with metastatic or advanced solid tumor that is not curable with local therapies
• Participants must have been treated with established standard-of-care therapy, andphysicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. In the latter case, the source documentation must state the effective therapies the participant is declining.
• Measurable disease (i.e., at least one measurable lesion per RECIST 1.1)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ function defined as:

a. Hepatic:

i. Serum ALT ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases

i. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases

ii. Serum bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome (typically elevated total bilirubin of 1-5 mg/dL with a normal direct bilirubin) or hemolysis)

b. Creatinine clearance >60 mL/minute using Modification of Diet in Renal Disease equation

c. Hematologic:

i. ANC ≥1,500/µL (>1,200/µL in Duffy antigen-null participants)

ii. Platelets ≥100,000/µL

iii. Hemoglobin ≥8 g/dL

• Participants must be willing and able to comply with all protocol-required assessments, visits, and procedures, including evaluable pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline.
• Females of childbearing potential must have negative serum pregnancy test prior to starting study therapy and agree to use a reliable form of contraceptive during the study treatment period and for at least 7 months following the last dose of study drug.
• Participants not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in the trial. Postmenopausal is defined as 12 months with no menses without an alternative medical cause. Male participants must agree to use an adequate method of contraception during the study treatment period and for at least 4 months following the last dose of study drug.
• Participants with human immunodeficiency virus (HIV) infection or with documented history of HIV infection are eligible if CD4+ T-cell counts are ≥350 cells/μL and have an HIV viral load less than 200 copies/mL prior to enrollment. Participants on ART should be on an established dose for at least 4 weeks under stable condition.
• Participants with serological evidence of chronic HBV infection or with documented history of HBV infection are eligible if they have an HBV viral load below the limit of quantification with or without concurrent viral suppressive therapy.
• Participants with a history of HCV infection can be under curative antiviral treatment and have a viral load below the limit of quantification.
• Participants in Phase 1b (Cohort Expansion) - must have one of the following tumor types to be enrolled in the respective cohort:

• Cohort 1: BTC (intra- and extrahepatic CCA, carcinoma of ampulla of Vater, and gallbladder disease)
• Cohort 2: Gastric and GEJ cancer
• Cohort 3: PROC

Exclusion criteria

• Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks, whichever is shorter, from prior biologic therapies, prior to the first dose of OBI-902.
• Participants that have undergone a major surgical procedure (as defined by the investigator) or significant traumatic injury within 28 days prior to the first dose of OBI-902.
• Sensory or motor neuropathy of Grade 2 or greater.
• Participants with a history of solid organ transplants. Corneal transplant without immunosuppressive therapy is allowed.
• Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using NCI CTCAE version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.
• Receipt of any prior therapy targeting TROP2. (Phase 2 only)
• Corrected QT interval (QTcF) prolongation to >470 msec based on the average of the screening 12-lead ECGs
• Known hypersensitivity to OBI-902 or its excipients.
• Participants with known untreated central nervous system (CNS) metastases. Participants with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the screening period.
• Participants with significant clinical cardiac abnormality (e.g., clinical heart failure or unstable angina).
• Any medical comorbidity that is life-threatening or, in the opinion of the Investigator, renders the participant unsuitable for participation in a clinical trial due to possible noncompliance, would place the participant at an unacceptable risk and/or potential to affect interpretation of results of the study.
• Participants who are pregnant or breastfeeding.
• Is receiving any concurrent prohibited medications as listed in OBI-902-001 clinical protocol.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 3 centers

• Scripps Green Hospital — La Jolla
• The University of Texas MD Anderson Cancer Center — Houston
• NEXT Oncology — San Antonio

Taiwan · 3 centers

• Wan Fan Hospital — Taipei
• Shuang Ho Hospital — Taipei
• China Medical University Hospital — Taichung

Identifiers

NCT: NCT07124117 · OBI-902-001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗